In the solid organ transplant infectious disease field, data have begun to emerge that certain mTOR inhibitors (used as anti-organ rejection medications) may have anti-viral properties, reducing the risk of some viral reactivation syndromes (Pascual et al., 2016). This evidence concerns the gene MTOR and infectious disease.